Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artrya Limited ( (AU:AYA) ) has shared an update.
Artrya Limited has announced that Mass General Brigham, a leading U.S. center for cardiac care, will participate in the SAPPHIRE Study, a retrospective multi-center trial set to begin in early 2026. This study aims to evaluate the clinical and prognostic value of Artrya’s Salix AI-powered platform in detecting coronary artery disease. The inclusion of Mass General Brigham, along with other high-volume U.S. cardiology sites, is expected to enhance Artrya’s presence in the U.S. market and support the company’s mission to improve early detection and management of heart disease.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company specializing in AI-powered solutions for the detection and management of coronary artery disease. The company’s proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in diagnosing patients more accurately and efficiently. Artrya is focused on advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 910,817
Technical Sentiment Signal: Buy
Current Market Cap: A$524.5M
See more data about AYA stock on TipRanks’ Stock Analysis page.